title: Prognostic Value of Angiogenesis and Survivin Expression in Patients with Glioblastoma.
abstract: OBJECTIVE
  Glioblastoma (GBM) is the most common and the most aggressive primary brain tumor with poor prognosis. We aimed to evaluate the association between immunohistochemical expression of survivin and angiogenic parameters (microvessel density and vascular pattern) in patients who underwent surgery for GBM.
  
  
  METHODS
  The pathology reports and also clinical and follow-up data of patients with GBM were retrospectively evaluated. Control tissues were obtained from the archive for each antibody (Survivin, CD 34). Then, control staining of these antibodies was performed. Vessels were evaluated according to the standardized assessment of vascular pattern.
  
  
  RESULTS
  Mean survival for classical vascular pattern was longer than bizarre vascular pattern (p < 0.001). The survival time of patients decreased with increasing score of survivin staining. There was a significant correlation between survivin and survival time (p < 0.001). There was no significant correlation between microvessel density and survival time (p > 0.05).
  
  
  CONCLUSIONS
  With these findings, it is considered that high expression of survivin, bizarre vascular pattern and development of secondary GBM correlates with the low survival rates, however microvessel density has no correlation with the survival rates. Since only malignant cells express survivin, it might be a target protein for the development of novel therapies.
authors.affiliation: Trakya University, School of Medicine, Department of Pathology, Edirne, Turkey.
authors.forename: Ebru
authors.initials: E
authors.lastname: Tastekin
authors.forename: Vuslat Yurut
authors.initials: VY
authors.lastname: Caloglu
authors.forename: Fulya Oz
authors.initials: FO
authors.lastname: Puyan
authors.forename: Burcu
authors.initials: B
authors.lastname: Tokuc
authors.forename: Murat
authors.initials: M
authors.lastname: Caloglu
authors.forename: Tulin Deniz
authors.initials: TD
authors.lastname: Yalta
authors.forename: Nuray
authors.initials: N
authors.lastname: Can
authors.forename: Beril
authors.initials: B
authors.lastname: Guler
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology; D005260:Female; D005909:Glioblastoma / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies; D000077022:Survivin; D055815:Young Adult
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin